VEGF-A and VEGF-B are proangiogenic and key regulating factors for blood vessel growth. This study aims to compare VEGF-A and VEGF-B levels in the serum and vitreous of patients with neovascular pathology versus non-neovascular pathology. Our findings showed vitreous VEGF-A and VEGF-B levels increased in patients with neovascular disease, with higher levels of VEGF-A compared to VEGF-B (p ≤ .05). In the diabetic retinopathy (DR) group, higher vitreous VEGF-A or VEGF-B were found in proliferative diabetic retinopathy (PDR) than in non-PDR. The strong correlation between VEGF-A and VEGF-B demonstrates a simultaneous pathological increase of cytokines (p < .001), suggesting besides VEGF-A, VEGF-B is another contributor to ocular pathologies involving angiogenesis. There was no correlation between vitreous and serum VEGF-A or VEGF-B; however, a correlation between vitreous (VEGF-A or VEGF-B) and macular volume (p < .05) in DR patients was found. Targeting VEGF-A and VEGF-B in macular and retinal vascular diseases, involving neovascularization, may improve treatment outcomes.

VEGF-A和VEGF-B是促血管生成和血管生长的关键调节因子。这项研究的目的是比较新血管病变和非新血管病变患者血清和玻璃体中的VEGF-A和VEGF-B水平。我们的研究结果表明玻璃体VEGF-A和VEGF-B的水平的患者新血管疾病增加，具有更高水平的VEGF-A的相比VEGF-B（p  ≤0.05）。在糖尿病性视网膜病（DR）组中，与非PDR相比，增生性糖尿病性视网膜病（PDR）中发现较高的玻璃体VEGF-A或VEGF-B。VEGF-A和VEGF-B之间的强相关性表明细胞因子同时发生病理性增加（p （<.001），这表明除VEGF-A外，VEGF-B是涉及血管生成的眼部病理的另一个原因。玻璃体和血清VEGF-A或VEGF-B之间没有相关性；然而， 在DR患者中发现了玻璃体（VEGF-A或VEGF-B）与黄斑体积（p <.05）之间的相关性。在涉及新血管形成的黄斑和视网膜血管疾病中靶向VEGF-A和VEGF-B可能会改善治疗效果。